Moroccan Minister of Endowments and Islamic Affairs Meets with Undersecretary of Saudi Ministry of Islamic Affairs    Saudi Ambassador to The Philippines Meets with Filipino Minister for National Commission on Muslim Filipinos    Al-Shagdali Meets Secretary-General of Red Sea Investors Association    Weather Forecast for Friday    HRH Crown Prince Crowns Winner Al-Fayhaa with the Custodian of the Two Holy Mosques' Cup 2021/2022    Jeddah Season 2022 Launches Japanese "Anime Village" with Largest Cosplay Parade    Taif Rose Festival Attracts Nearly 1 Million Visitors, Concludes with Great Success    Saudi Arabia Heads to Cannes International Film Festival to Promote Country's Flourishing Industry and Support Emerging Talent on World Stage    King, Crown Prince congratulate President Paul Biya on Cameroon's National Day    Saudi Arabia delivers humanitarian aid worth $3.2 million to Philippines    Capital Economics expects Saudi economy to grow 10% in 2022    ZATCA clarifies conditions for buying and bringing cars from abroad    Sri Lanka defaults on debt for first time in its history    Global economic growth downgraded due to spillover from Ukraine war    Saudi Arabia took important steps to enhance food security, says minister    Nations must act together to end crisis of food insecurity: UN chief    India seeks to win public trust in crisis-hit Sri Lanka    Russian soldier pleads guilty in first war crimes trial of Ukraine conflict    Three Professors Win 2022 IsDB Prize for Impactful Achievement in Islamic Economics    Saudi Arabia bags two gold medals at GCC Games    Salman bin Ibrahim to seek third term at AFC helm    US Soccer equalizes pay in milestone with women, men    Prince Khalid, Austin review Saudi-US defense ties    Hospital admissions for eating disorders soar in Britain    Saudis in Cannes: Promoting country's flourishing film industry    Saudi Stock Exchange Main Index Ends Trading Lower at 12,427.96 Points    Japan Posts Trade Deficit of 839.2 Billion Yen in April    Asian Shares Fall    Prince Faisal, Lamamra review historical ties; discuss enhancing joint cooperation    Saudi Tourism Authority Signs Over 90 Agreements and MoU in Dubai ATM 2022    President of SAFF Participates in AFC General Assembly Meeting    36 films compete for 12 awards at Saudi Film Festival    Senegalese show support to Idrissa Gueye after homophobia accusations    Saudi Athletes Achieve Great Victories in the 2nd Day of the GCC Games Tournament in Kuwait    Kay Mellor: Actress and Fat Friends creator dies aged 71    Jazan Hosts West Asian Beach Soccer Championship    Over 250 Saudi Female and Male Players to Participate in Kuwait 3rd GCC Games on Friday    Bollywood actor's tweet reignited debate over Hindi as India's national language    SFDA Advises to Wash Dates Well Before Eating    SFDA Advises Against Mixing Surplus of Iftar and Suhoor with Different Foods or Surplus from Other Days    Ministry calls on imams to avoid long supplications in Tahajjud Prayer    Nothing wrong with a Muslim celebrating birthdays, says Saudi scholar    Ranbir Kapoor and Alia Bhatt: Bollywood wishes for star couple on wedding    SFDA Warns Against Microbes Accumulation on Coffee when Stored Incorrectly    Custodian of the Two Holy Mosques addresses citizens and all Muslims on the occasion of the Holy month of Ramadan    Pilgrims Perform Dhuhr and Asr Prayers at Arafat Holy Site    Council of Senior Scholars: Muslim Brothers' Group Don't Represent Method of Islam, rather only Follows its Partisan Objectives, Violating our Graceful Religion    Eid Al-Adha Prayer Performed at the Grand Holy Mosque    







Thank you for reporting!
This image will be automatically disabled when it gets reported by several people.



Alzheimer's experts see progress on new drugs
Published in The Saudi Gazette on 02 - 08 - 2008

Despite some recent dramatic failures, Alzheimer's disease researchers say they have never been more encouraged by the wealth of promising new treatments being studied for the brain-wasting disease.
“Twenty years ago we were at zero,” said Dr. Steven DeKosky of the University of Pittsburgh, who has been studying the problem of addressing Alzheimer's for three decades.
DeKosky led one of three panels focused on new therapies featured this week at the International Conference on Alzheimer's Disease in Chicago.
There is no cure for Alzheimer's, the most common form of dementia, and current drugs merely delay symptoms a bit.
While the most advanced drugs have focused on removing clumps of beta amyloid protein that forms plaques in the brain, researchers got their first look at therapies to address the toxic tangles caused by an abnormal build-up of the protein tau.
One, a nasal spray made by Allon Therapeutics Inc, improved some measures of memory in patients with mild cognitive impairment, a precursor to Alzheimer's, researchers reported this week.
They said findings from the three-month study were strong enough for a longer, larger study.
Another, called Rember, is a refined version of an older drug used to treat urinary tract infections called methylthioninium chloride or methylene blue.
Researchers said the drug significantly improved key measures of thinking and memory in some people with moderate Alzheimer's disease for more than a year- and- a -half.
Targeting the tangle
“We now show for the first time it is possible to halt the progression of Alzheimer's disease by targeting the tangle,” Claude Wischik, of the University of Aberdeen in Scotland and chairman of TauRX Therapeutics in Singapore, told the meeting.
Wischik said he thinks the compound keeps the tau protein from forming tangles inside brain cells and eventually from bursting them open.
“I can't make any statements about safety and efficacy,” he added.
Another promising drug is Medivation Inc's Dimebon, developed in Russia as an antihistamine.
An 18-month study of 183 patients done in that country showed it was safe and produced a persistent benefit.
How Dimebon works is not clear. Researchers said it may help protect mitochondria, the energy powerhouses of cells.
“It has many effects as opposed to having one single effect,” said Dr. Scott Turner, the incoming director of the Memory Disorders Program at Georgetown University Medical Center in Washington.
Turner said more studies will be needed to show whether Dimebon offers an advance over current treatments.
New attempts at targeting beta amyloid include a drug called PBT2 from Prana Biotechnology Ltd, which aims to keep beta amyloid from interacting with copper and zinc in the brain, a process involved in plaque formation.
In another new approach, Baxter International Inc said an intravenous therapy of antibodies derived from human plasma called Gammagard helped preserve and in some cases improve cognitive function in a nine-month study.
“We're fascinated by the mechanism, but we know nothing about whether it will be useful long-term,” DeKosky said of the study.
Disappointing path
This path of attempting to alter the course of Alzheimer's by attacking beta amyloid has been littered with disappointments.
Last August, a drug by Canadian biotech Bellus Health, formerly known as Neurochem Inc, failed to show a benefit in a study of more than 1,000 patients.
Last month, Flurizan, also known as tarenflurbil, failed to help patients in a pivotal clinical test, dealing a blow to its backers Myriad Genetics and Lundbeck.
This week, shares of Elan and Wyeth plunged on news of a weaker-than-hoped-for response in a mid-stage study of its new antibody therapy bapineuzumab. Researchers are still hopeful this drug, or one like it, will work.
“There are lots of curve balls in this research and we are not having an easy time,” said Marcelle Morrison-Bogorad, director of Alzheimer's research at the National Institute on Aging.
Meanwhile, the need for effective therapies is pressing.
An estimated 5.2 million people in the United States have Alzheimer's, according to the Alzheimer's Association, and 26 million globally -- a number projected to grow to 106 million by 2050. – Reuters __


Clic here to read the story from its source.